Editorial draft — not for publication yet. Bromazepam content needs clinical and legal review before publication. This page is general information and is not advice about an individual prescription.

In short

Bromazepam is a benzodiazepine used as a medicine in some countries. UK government sources list it as a Class C, Schedule 4 Part I controlled drug and ACMD guidance does not list it as a UK-licensed medicine. The Irish-authorised Lexotan leaflet describes severe anxiety for that product, but it is not UK treatment guidance. Do not copy overseas doses, buy unverified tablets or stop regular benzodiazepine use suddenly without medical advice.

Bromazepam UK status

The Advisory Council on the Misuse of Drugs’ 2026 benzodiazepine list places bromazepam among substances not licensed as medicines in the UK. The Home Office controlled-drugs list updated 1 April 2025 records bromazepam as Class C, Schedule 4 Part I. These are separate facts: controlled-drug scheduling is not a UK marketing authorisation. The Irish HPRA lists a specific Lexotan product; that Irish approval and leaflet do not establish UK authorisation or make an overseas pack suitable for an individual.

What do overseas product documents say about bromazepam?

The Irish HPRA Lexotan leaflet describes bromazepam for severe anxiety and the shortest possible treatment period. This applies to that Irish-authorised product, not a UK marketing authorisation. In the UK, NICE guidance says benzodiazepines should only be a short-term crisis measure for generalised anxiety disorder and should not be prescribed for panic disorder.

  • Bromazepam is a benzodiazepine active ingredient found in medicines authorised in some countries.
  • The Irish HPRA Lexotan leaflet describes use for severe anxiety; this is product-specific Irish information, not UK prescribing guidance.
  • Bromazepam is not listed as a UK-licensed medicine in the cited ACMD list; a foreign product authorisation does not transfer to the UK.
  • For anxiety symptoms in the UK, a GP or mental-health professional can assess the cause and discuss NICE-based treatment options.
  • The Home Office lists bromazepam separately as Class C, Schedule 4 Part I; legal scheduling does not make an overseas product UK-licensed.

NICE applies benzodiazepine guidance at class level: for GAD, use only as a short-term measure during a crisis; do not prescribe benzodiazepines for panic disorder because of poorer long-term outcomes.

NICE says dependence risk should be discussed before treatment and recommends a slow, stepwise, individualised plan for benzodiazepine withdrawal in most cases.

The cited Lexotan Summary of Product Characteristics and patient leaflet are Irish sources. They are included for transparent product context, not as UK authorisation or a personal treatment recommendation.

How does it work?

Bromazepam is a benzodiazepine. The Irish Lexotan product information classifies it as an anxiolytic and describes effects consistent with the benzodiazepine class, including sedation and impaired alertness. A drug’s class does not determine whether a particular product is licensed or appropriate in the UK.

Risks and possible effects

Sleepiness and impaired coordination

The Irish Lexotan leaflet lists drowsiness, tiredness, reduced alertness, dizziness, confusion, headache, nausea, weak muscles, unsteadiness and double vision. Details can differ between product and country.

Severe sedation or breathing problems

Alcohol, opioids and other sedatives may intensify benzodiazepine effects. Call 999 if someone is unconscious, cannot be woken, collapses, has a seizure or has slow or difficult breathing.

Safety information

  • Bromazepam is listed by the Home Office as Class C, Schedule 4 Part I and is not listed as a UK-licensed medicine in ACMD guidance. Check the exact product and current rules with a qualified UK professional.
  • Benzodiazepines can cause dependence and withdrawal. Do not stop regular use suddenly or follow a dose-conversion or tapering chart from the internet.
  • Avoid alcohol while taking the cited Lexotan product. Do not combine bromazepam with opioids, sleeping tablets or other sedatives unless a prescriber has explicitly assessed the combination.
  • The Irish product leaflet warns about severe breathing or liver problems, myasthenia gravis and sleep apnoea. This list is not a UK suitability assessment; share your full health history with a clinician.
  • Bromazepam can cause sleepiness, poor concentration and slower reactions. Do not drive or operate machinery if impaired; UK rules and local guidance apply.
  • If pregnant, planning pregnancy or breastfeeding, contact a doctor or pharmacist with the exact product details. Do not abruptly stop regular use without advice.

Bromazepam for anxiety: overseas product information and NICE context

The Irish Lexotan leaflet describes bromazepam for severe anxiety. NICE guidance for GAD says benzodiazepines should only be used as a short-term measure during a crisis; for panic disorder, NICE advises against prescribing benzodiazepines because of poorer long-term outcomes. This is class-level UK guidance and should not be read as a recommendation to use bromazepam.

A GP can assess anxiety and discuss psychological care and medicine options that are appropriate in the UK. A foreign indication does not replace assessment or make a product licensed here.

Sleepiness is a possible effect, not a UK insomnia recommendation

Bromazepam may cause drowsiness, but sedation alone does not show that it is a suitable insomnia treatment. The cited Irish leaflet lists severe anxiety for its specific product; ACMD guidance does not list bromazepam as a UK-licensed medicine.

NHS guidance recommends considering causes of persistent insomnia and contacting a GP if sleep problems continue or affect daily life. Do not take bromazepam that was not prescribed to you.

The ACMD 2026 list identifies bromazepam among benzodiazepines not licensed as medicines in the UK. Separately, the Home Office list updated 1 April 2025 classifies it as Class C, Schedule 4 Part I. A controlled-drug schedule does not establish that a brand or pack has UK marketing authorisation.

The Irish HPRA record for Lexotan is specific to Ireland. For an overseas prescription, imported pack or travel question, consult current GOV.UK guidance and ask a UK pharmacist or the Home Office DFLU.

Overdose and urgent help

If you think someone has swallowed a harmful amount, NHS poisoning guidance says to call 999 or go to A&E. Call 999 immediately for unconsciousness, a seizure, collapse or severe breathing problems. Do not wait for symptoms to worsen.

Stay with the person, do not make them vomit, and keep the pack available for clinicians. If the substance or amount is uncertain and there are no emergency symptoms, NHS 111 can advise what to do.

Frequently asked questions

Is bromazepam licensed in the UK?

The ACMD 2026 benzodiazepine list places bromazepam among substances not licensed as medicines in the UK. A product authorised in Ireland or another country is not thereby UK-licensed.

What class and schedule is bromazepam in the UK?

The Home Office list updated 1 April 2025 records bromazepam as Class C, Schedule 4 Part I. This is separate from product licensing.

Is bromazepam used for anxiety?

The Irish Lexotan leaflet describes its product for severe anxiety. NICE UK guidance limits benzodiazepines for GAD to short-term crisis use and advises against them for panic disorder; it does not recommend bromazepam specifically.

Can I stop bromazepam suddenly?

Do not stop regular benzodiazepine use suddenly without medical advice. NICE recommends a slow, individualised reduction plan in most cases.

What should I do if someone takes too much bromazepam?

Follow NHS poisoning advice: call 999 or go to A&E if a harmful amount may have been swallowed. Call 999 immediately for unconsciousness, seizure, collapse or breathing problems.

Explore the detailed bromazepam guides

Each guide answers a different practical question. Advice is specific to bromazepam and should be checked against your own product leaflet and prescription.

Sources and review

This draft was checked against the sources below on 3 October 2026. It still requires clinical and legal review before publication.

Editorial status: Clinical and regulatory review required before publication.